目的:研究骨钙素在使用BMP2/7异源二聚体促进种植体周骨缺损再生中的表达.方法:建立小型猪种植体周骨缺损模型,并使用BMP2/7异源二聚体及BMP2、BMP7同源二聚体促进骨再生,采用免疫组化方法分别在2、3、6周时检测新骨中骨钙素表达.结果:在各实验组中,骨钙素3周时表达达到最高值.在2、3、6周,BMP2/7组骨钙素表达均强于BMP2、BMP7同源二聚体组及对照组.结论:在以同样较低浓度(30ng/ml)作用于小型猪种植体周骨缺损诱导新骨形成过程中,BMP2/7异源二聚体较BMP、BMP7同源二聚体有效促进骨钙素的表达.%To delineate expression of osteocalcin induced by recombinant human bone morphogenetic protein (BMP)2/7 heterodimer in peri-implant bone defects in comparison to BMP2 and BMP7 homodimer.Methods: Identical peri-implant bone defects were created on the frontal skull of minipig. Collagen sponges with the same dose BMP2/7 heterodimer、 BMP2 homodimer 、 BMP7 homodimer 、 or BMPs were adopted to treat the freshly created implant bed. Titanium implants were centrally implanted with 4mm-flxture within bone defects. Immunohistochemical method was applied to evaluate the expression of osteocalcin (OCN) after 2, 3, and 6 weeks of implantation. Results: The OCN proteins displayed intensity peaks at 3 weeks (P<0.05) in all the groups. Immunoreactive expression of OCN of BMP2/7 group was more intensity than BMP2、 BMP7 and control group at 2, 3, and 6 weeks post-operation (P<0.05). Conclusions: Purified recombinant human BMP2/7 heterodimer can enhance the expression of OCN with significant differences over BMP2 homodimers or BMP7 homodimers with the same low-dose (30ng/ml).
展开▼
